Breast cancer

Summary

The Breast cancer research group aims to better understand breast cancer development, the origin of disease subtypes, and disease progression and vulnerabilities. The research projects comprise the major disease subtypes as well as BRCA1/2-mutant breast cancer. The group also works to develop novel targeted preventive approaches and to improve the quality of life of patients. This is a multidisciplinary team that combines the experience and knowledge of clinical and translational researchers.

320 Publications

Strategic lines

Selected Publications

Villacampa,G;Tung,NM;Pernas,S;Paré,L;Bueno Muiño,C;Echavarría,I;López Tarruella,S et al, Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer, Ann. Oncol., 2023;34(9):doi:10.1016/j.annonc.2023.05.012
Oliveira,M;Falato,C;Cejalvo,JM;Vila,MM;Tolosa,P;Salvador Bo,FJ;Cruz,J et al, Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study, Ann. Oncol., 2023;34(8):670-680, doi:10.1016/j.annonc.2023.05.004
Patel,PS;Algouneh,A;Krishnan,R;Reynolds,JJ;Nixon,KCJ;Hao,J;Lee,J et al, Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers., Nucleic Acids Res., 2023;51(9):4341-4362, doi:10.1093/nar/gkad172
Krishnan,R;Lapierre,M;Gautreau,B;Nixon,KCJ;El Ghamrasni,S;Patel,PS;Hao,J et al, RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells, Nucleic Acids Res., 2023;51(19):10484-10505 doi:10.1093/nar/gkad733,
Ciscar,M;Trinidad,EM;Perez Chacon,G;Alsaleem,M;Jimenez,M;Jimenez Santos,MJ;Perez Montoyo,H et al, RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer., EMBO Mol. Med. 2023;15(4):doi:10.15252/emmm.202216715

Selected Projects

LCX21020. Becas de posdoctorado Junior Leader Incoming. FUNDACIÓ "LA CAIXA". Budget: 297.900€. 2022-2025. PI: GENESTAR PUJANA, MIGUEL ANGEL.
2023-595-1. A PHASE 3, OPEN-LABEL, RANDOMIZED, TWO-PART STUDY COMPARING GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND FULVESTRANT TO STANDARD-OF-CARE THERAPIES IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH A CDK4/6 INHIBITOR IN COMBINATION WITH NON-STEROIDAL AROMATASE INHIBITOR THERAPY (VIKTORIA-1). CELCUITY INC. Budget: 253.918€. 2023- . PI: Stradella Trucco, Agostina.
2022-061-1. Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo, con un periodo de preinclusión con un solo grupo, para evaluar la seguridad y la eficacia de un colirio de tiosulfato de sodio (BYON5667) para reducir la toxicidad ocular en pacientes oncológicos tratados con SYD985. BYONDIS B.V.;Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) . Budget: 221.291€. 2022- . PI: Stradella Trucco, Agostina.
2021-037-1. SERENA-4: Ensayo de fase III aleatorizado, multicéntrico, doble ciego, de AZD9833 (un SERD, Degradador selectivo del RE, oral) más palbociclib en comparación con anastrozol más palbociclib para el tratamiento de pacientes con cáncer de mama avanzado con receptores estrogénicos positivos y HER2 negativo que no han recibido ningún tratamiento sistémico para la enfermedad avanzada. Astrazeneca Farmacéutica Spain, S.A. Budget: 218.253€. 2021- . PI: OBADIA GIL, VERONICA LUISA.
FIS22070. CONTRATOS MIGUEL SERVET. Instituto de Salud Carlos III (ISCIII). Budget: 202.500€. 2023-2028. PI: ANTOLIN HERNANDEZ, ALBERT.

Technology transfer

More Information

The group has extensive experience in bioinformatic and systems biology approaches, combined with in vitro and in vivo experimental studies, aimed at better understanding the development and progression of breast cancer. Over the past five years, the team has published 50 articles on a regular basis, including various manuscripts in leading journals. The team has also received various national and international grants and has established strong collaborations with national and international leaders in the area.